Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure

I. E. Beldhuis, J. M. ter Maaten, S. M. Figarska, K. Damman, P. S. Pang, B. Greenberg, B. A. Davison, G. Cotter, T. Severin, C. Gimpelewicz, G. M. Felker, G. Filippatos, J. R. Teerlink, M. Metra, A. A. Voors*

*Corresponding author voor dit werk

OnderzoeksoutputAcademicpeer review

2 Citaten (Scopus)
17 Downloads (Pure)

Samenvatting

Background: We aimed to study whether improvement in renal function by serelaxin in patients who were hospitalized for acute heart failure (HF) might explain any potential effect on clinical outcomes. 

Methods: We included 6318 patients from the RELAXin in AHF-2 (RELAX-AHF2) study. Improvement in renal function was defined as a decrease in serum creatinine of ≥ 0.3 mg/dL and ≥ 25%, or increase in estimated glomerular filtration rate of ≥ 25% between baseline and day 2. Worsening renal function (WRF) was defined as the reverse. We performed causal mediation analyses regarding 180-day all-cause mortality (ACM), cardiovascular death (CVD), and hospitalization for HF/renal failure. 

Results: Improvement in renal function was more frequently observed with serelaxin when compared with placebo [OR 1.88 (95% CI 1.64–2.15, p < 0.0001)], but was not associated with subsequent clinical outcomes. WRF occurred less frequent with serelaxin [OR 0.70 (95% CI 0.60–0.83, p < 0.0001)] and was associated with increased risk of ACM, worsening HF and the composite of CVD and HF or renal failure hospitalization. Improvement in renal function did not mediate the treatment effect of serelaxin [CVD HR 1.01 (0.99–1.04), ACM HR 1.01 (0.99–1.03), HF/renal failure hospitalization HR 0.99 (0.97–1.00)]. 

Conclusions: Despite the significant improvement in renal function by serelaxin in patients with acute HF, the potential beneficial treatment effect was not mediated by improvement in renal function. These data suggest that improvement in renal function might not be a suitable surrogate marker for potential treatment efficacy in future studies with novel relaxin agents in acute HF. 

Originele taal-2English
Pagina's (van-tot)901-910
Aantal pagina's10
TijdschriftClinical Research in Cardiology
Volume112
Nummer van het tijdschrift7
DOI's
StatusPublished - jul.-2023

Vingerafdruk

Duik in de onderzoeksthema's van 'Disconnect between the effects of serelaxin on renal function and outcome in acute heart failure'. Samen vormen ze een unieke vingerafdruk.

Citeer dit